Suceagu

Researchers are studying how well and safely orforglipron works in adult women who have stress urinary incontinence (SUI) and are overweight or have obesity. SUI is a condition where urine leaks during movements like coughing or exercising. This trial is part of a master protocol including two independent studies, and it is a Phase 3 clinical trial. Participants will be randomly assigned to receive either orforglipron tablets or a placebo, both taken orally once daily. The treatment period and study participation will last approximately 58 weeks, including screening and safety follow-up. The study compares the effects of orforglipron against placebo in this specific group of female patients. During the study, researchers will track changes in the frequency of incontinence episodes from the start to week 52. Participants will undergo screening, treatment, and safety monitoring throughout the trial. The study aims to assess the effectiveness and safety of orforglipron in reducing urinary leakage events over time.

Researchers are evaluating ivonescimab as a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors show high PD-L1 expression. This phase 3 randomized, double-blinded study compares ivonescimab with pembrolizumab to assess overall survival and progression-free survival in this patient group. Participants will receive either ivonescimab or pembrolizumab as intravenous injections. The study is designed to monitor these treatments over time to determine which may provide better outcomes in controlling metastatic NSCLC in patients with high PD-L1 levels. The study includes patients with measurable non-brain lesions and no prior systemic treatment for metastatic NSCLC. During the trial, patients will be closely followed for up to approximately 36 months to measure overall survival and progression-free survival. Researchers will assess the safety and effectiveness of the treatments through regular evaluations, including monitoring for disease progression and survival status. This long-term follow-up ensures comprehensive understanding of treatment impact over time.